Benzinga | Jun 1, 2021 09:38AM EDT

Paratek's Stock Gains After Nuzyra's Oral Regime Wins FDA Approval For Pneumonia

* The FDA has approved Paratek Pharmaceuticals Inc's (NASDAQ:PRTK) supplemental marketing application for the oral-only dosing regimen of Nuzyra for Community-Acquired Bacterial Pneumonia (CABP).

* The approval of an oral-only dose regimen for NUZYRA represents a significant opportunity to treat patients in either the outpatient or primary care setting to potentially reduces/eliminates hospitalizations and the associated risk and costs from a hospital stay, the company said.

* The FDA approved Nuzyra in 2018 as an antibiotic with both once-daily oral and intravenous formulations to treat CABP and acute bacterial skin and skin structure infections.

* Price Action: PRTK shares are up 7.6% at $8.84 during the market session on the last check Tuesday.